{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:16:48Z","timestamp":1756383408631,"version":"3.44.0"},"reference-count":33,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,5,2]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Cannabis withdrawal syndrome (CWS) presents with irritability, anxiety and sleep disturbances within a week of stopping cannabis use. This case highlights a young woman with a medical history of recurrent hospitalisations due to intractable nausea and vomiting related to heavy, prolonged cannabis use and acute dystonic reactions secondary to haloperidol. The patient presented with intractable nausea, vomiting and frequent hot bathing five days after her last cannabis use. She developed an acute dystonic reaction to low-dose metoclopramide, a commonly used antiemetic, potentially exacerbated by cannabis\u2019s inhibition of drug-metabolising enzymes. We also highlight key differences between CWS and cannabis hyperemesis syndrome (CHS).<\/jats:p>","DOI":"10.1136\/bcr-2025-264815","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:25:21Z","timestamp":1747387521000},"page":"e264815","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Low-dose metoclopramide-induced dystonia in cannabis withdrawal syndrome manifesting as intractable nausea and vomiting"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-5372","authenticated-orcid":false,"given":"Alia","family":"Khamis","sequence":"first","affiliation":[{"name":"Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA"},{"name":"Internal Medicine, Garnet Health Medical Center, Middletown, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Dygulski","sequence":"additional","affiliation":[{"name":"Touro College of Osteopathic Medicine, Middletown, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2025082804280094000_18.5.e264815.1","unstructured":"SAMHSA . 2023 NSDUH Detailed Tables. 2023. Available: https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-detailed-tables"},{"key":"2025082804280094000_18.5.e264815.2","unstructured":"SAMHSA . Highlights for the 2023 national survey on drug use and health. 2023. Available: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH%202023%20Annual%20Release\/2023-nsduh-main-highlights.pdf"},{"key":"2025082804280094000_18.5.e264815.3","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jamapsychiatry.2015.1858","article-title":"Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013","volume":"72","author":"Hasin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2025082804280094000_18.5.e264815.4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.28934","article-title":"Prevalence of Cannabis Use Disorder and Reasons for Use Among Adults in a US State Where Recreational Cannabis Use Is Legal","volume":"6","author":"Lapham","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025082804280094000_18.5.e264815.5","unstructured":"APA . Substance-related and addictive disorders. In: Diagnostic and statistical manual of mental disorders: DSM-5-TR. Washington DC, 2022."},{"key":"2025082804280094000_18.5.e264815.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2370","article-title":"Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis","volume":"3","author":"Bahji","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025082804280094000_18.5.e264815.7","doi-asserted-by":"publisher","DOI":"10.1111\/add.15743"},{"key":"2025082804280094000_18.5.e264815.8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1742-6723.13944","article-title":"Cannabinoid hyperemesis syndrome: A 6-year audit of adult presentations to an urban district hospital","volume":"34","author":"Rotella","year":"2022","journal-title":"Emerg Med Australas"},{"key":"2025082804280094000_18.5.e264815.9","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-016-0595-z"},{"key":"2025082804280094000_18.5.e264815.10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12245-022-00446-0","article-title":"Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department","volume":"15","author":"Razban","year":"2022","journal-title":"Int J Emerg Med"},{"key":"2025082804280094000_18.5.e264815.11","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/apt.17265","article-title":"Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence","volume":"56","author":"Andrews","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025082804280094000_18.5.e264815.12","first-page":"654","article-title":"Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry","volume":"34","author":"Sandhu","year":"2021","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2025082804280094000_18.5.e264815.13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/add.16693","article-title":"Rare but relevant: Cannabinoid hyperemesis syndrome","volume":"120","author":"Stjepanovi\u0107","year":"2025","journal-title":"Addiction"},{"key":"2025082804280094000_18.5.e264815.14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1053\/j.gastro.2024.06.026","article-title":"Comments on the AGA Clinical Practice Update on Diagnosis and Management of Cannabinoid Hyperemesis Syndrome","volume":"167","author":"Mullins","year":"2024","journal-title":"Gastroenterology"},{"key":"2025082804280094000_18.5.e264815.15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jemermed.2017.12.010","article-title":"Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department","volume":"54","author":"Richards","year":"2018","journal-title":"J Emerg Med"},{"key":"2025082804280094000_18.5.e264815.16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/14656566.2022.2049237","article-title":"Pharmacological management of cannabinoid hyperemesis syndrome: an update of the clinical literature","volume":"23","author":"Burillo-Putze","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2025082804280094000_18.5.e264815.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2020.08.021"},{"key":"2025082804280094000_18.5.e264815.18","doi-asserted-by":"crossref","first-page":"106991","DOI":"10.1016\/j.addbeh.2021.106991","article-title":"Cannabis and mental health: Prevalence of use and modes of cannabis administration by mental health status","volume":"121","author":"Rup","year":"2021","journal-title":"Addict Behav"},{"key":"2025082804280094000_18.5.e264815.19","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-14-136","article-title":"A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies","volume":"14","author":"Kedzior","year":"2014","journal-title":"BMC Psychiatry"},{"key":"2025082804280094000_18.5.e264815.20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12967-020-02518-2","article-title":"Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties","volume":"18","author":"Sharpe","year":"2020","journal-title":"J Transl Med"},{"key":"2025082804280094000_18.5.e264815.21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/acem.14911","article-title":"Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department","volume":"31","author":"Borgundvaag","year":"2024","journal-title":"Acad Emerg Med"},{"key":"2025082804280094000_18.5.e264815.22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12883-023-03259-7","article-title":"The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials","volume":"23","author":"Abdelmonem","year":"2023","journal-title":"BMC Neurol"},{"key":"2025082804280094000_18.5.e264815.23","doi-asserted-by":"publisher","DOI":"10.1586\/eem.10.41"},{"key":"2025082804280094000_18.5.e264815.24","unstructured":"Hospira I . Metoclopramide injection, usp adverse reactions. Pfizer; 2023."},{"key":"2025082804280094000_18.5.e264815.25","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/PEC.0000000000001960","article-title":"Metoclopramide-Induced Acute Dystonia: Data From a Pediatric Emergency Unit","volume":"37","author":"Yarar","year":"2021","journal-title":"Pediatr Emerg Care"},{"key":"2025082804280094000_18.5.e264815.26","doi-asserted-by":"publisher","DOI":"10.1017\/S003329170003960X"},{"key":"2025082804280094000_18.5.e264815.27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00931","article-title":"Metoclopramide-Induced Acute Dystonic Reactions May Be Associated With the CYP2D6 Poor Metabolizer Status and Pregnancy-Related Hormonal Changes","volume":"10","author":"Chua","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025082804280094000_18.5.e264815.28","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.041384"},{"key":"2025082804280094000_18.5.e264815.29","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1055481","article-title":"Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions","volume":"13","author":"Smith","year":"2022","journal-title":"Front Psychiatry"},{"key":"2025082804280094000_18.5.e264815.30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2023.07.029","article-title":"Cannabidiol\u2019s impact on drug-metabolization","volume":"118","author":"St\u00f6llberger","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2025082804280094000_18.5.e264815.31","unstructured":"Rahman S , Marwaha R . Haloperidol. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC, 2025."},{"key":"2025082804280094000_18.5.e264815.32","unstructured":"Lewis K , O\u2019Day CS . Dystonic reactions. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC, 2024."},{"key":"2025082804280094000_18.5.e264815.33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00406-018-0970-7","article-title":"Cannabis and mental illness: a review","volume":"269","author":"Lowe","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-264815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:28:12Z","timestamp":1756380492000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-264815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,16]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bcr-2025-264815"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-264815","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}